Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228026 · ClinicalTrials.gov registry record
Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
A clinical trial of Asthma, sponsored by Biometry.
- Recruiting
- Registry status
- 160
- Enrollment target
- 13
- Study locations
NCT07228026: Recruiting study of Asthma, sponsored by Biometry.
NCT07228026 is a study of Asthma that is actively recruiting participants, run by Biometry. The registered enrollment target is 160 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (90% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228026, a study of Asthma, is actively recruiting participants, sponsored by Biometry.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study incorporates objectives directed at two subject cohorts: 1. Uncontrolled Adult and Pediatric Asthma Subjects: To demonstrate a statistically significant and clinically meaningful decline in Point Of Care (POC) FeNO as measured by the fenoTRACK device, after an approximately 2-week course of corticosteroid therapy in adults and children with non-steroid treated uncontrolled asthma. 2. Controlled Adult and Pediatric Asthma Subjects: * To evaluate within-session clinical precision during Visit 1 and Visit 2 for the fenoTRACK device for simulated at home FeNO, and at POC * To evaluate within-session clinical precision for home fenoTRACK use
Primary Outcome
Magnitude of change, expressed both as absolute and percentage change in FeNO values in the uncontrolled cohort from Visit 1 to Visit 2.
Conditions Studied
Interventions
- DEVICE fenoTRACK Device
Study Locations (13)
Texas
- Orion Clinical Research - Austin
- Pharmaceutical Research & Consulting, Inc. - Dallas
- Western Sky Medical Research - El Paso
Maryland
- AllerVie Clinical Research - Ellicott City
- AllerVie Clinical Research - Glenn Dale
California
- Bensch Clinical Research LLC - Stockton
Florida
- AllerVie Clinical Research - Panama City
Georgia
- AllerVie Clinical Research - Columbus
Maine
- Paul A Shapero MD - Bangor
Nebraska
- Nebraska Medical Research Institute, Inc. - Bellevue
North Carolina
- Allergy Partners Clinical Research - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2026-09-30 |
What NCT07228026 shows while recruiting
NCT07228026 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which fenoTRACK Device is the first listed.
NCT07228026 lists 13 locations in 10 states (Texas, Maryland, California).
Frequently Asked Questions
What is clinical trial NCT07228026 about?
NCT07228026 is a clinical study titled "Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects". This study incorporates objectives directed at two subject cohorts: 1. Uncontrolled Adult and Pediatric Asthma Subjects: To demonstrate a statistically significant and clinically meaningful decline in Point Of Care (POC) FeNO as measured by the fenoTRACK device, after an approximately 2-week course...
What is the current status of trial NCT07228026?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2025-09-17. Estimated completion is 2026-09-30.
What conditions does trial NCT07228026 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT07228026?
The interventions under investigation include: fenoTRACK Device (DEVICE).
Who is sponsoring clinical trial NCT07228026?
This trial is sponsored by Biometry, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228026 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Maine, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07228026's enrollment target sits among peer trials
160 181st of 374 higher than 193 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI